Russia's COVID-19 treatment drug may get approval by end of 2022: Gamaleya's deputy head

Deputy head Logunov said Gamaleya has developed chemical compounds to manufacture COVID-19 medicines, and one is based on monoclonal antibodies treatment.

Related Keywords

United Kingdom ,Russia ,Britain ,Donald Trump ,Robertm Davis ,Ridgeback Biotherapeutics ,Vladimir Putin ,Denis Logunov , ,President Vladimir Putin ,Gamaleya ,Covid 19 ,Covid Drug ,Russian Covid 19 Treatment Drug ,Russia Covid Cases ,